Drug Profile
Research programme: recombinant butyrylcholinesterase - AntoXa Corporation
Alternative Names: BuChE - Antoxa Corporation; rBuChE - AntoXa CorporationLatest Information Update: 15 Sep 2022
Price :
$50
*
At a glance
- Originator AntoXa Corporation
- Class Antidotes; Butyrates; Cholinesterases
- Mechanism of Action Scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Poisoning